专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

EA019115B1 АРИЛ- И ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ТЕТРАГИДРОБЕНЗАЗЕПИНЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ БЛОКИРОВКИ ОБРАТНОГО ЗАХВАТА НОРЭПИНЕФРИНА, ДОПАМИНА И СЕРОТОНИНА 未知
公开(公告)号：EA019115B1
公开(公告)日：2014-01-30
申请号：EA200800341
申请日：2006-07-17
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： MOLINO BRUCE F , LIU SHUANG , SAMBANDAM ARUNA , GUZZO PETER R , HU MIN , ZHA CONGXIANG , NACRO KASSOUM , MANNING DAVID D , ISHERWOOD MATTHEW L , FLEMING KRISTEN N , CUI WENGE , OLSON RICHARD E
IPC分类号： A61P25/00 , A61K31/55 , C07D223/16 , C07D403/02 , C07D487/02
摘要： Соединениясогласноизобретениюпредставленыследующимиарил- игетероарилзамещеннымипроизводнымитетрагидробензазепинаи дигидробензазепина, имеющимиформулы I (A-E) и (II), вкоторыхатомуглерода, обозначенный *, находитсяв конфигурации R или S, азаместители X и R-Rимеютзначения, определенныев описании.

2. 发明专利

AU2012202570A1 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin 未知
公开(公告)号：AU2012202570A1
公开(公告)日：2012-05-24
申请号：AU2012202570
申请日：2012-05-02
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： MOLINO BRUCE F , LIU SHUANG , SAMBANDAM ARUNA , GUZZO PETER R , HU MIN , ZHA CONGXIANG , NACRO KASSOUM , MANNING DAVID D , ISHERWOOD MATTHEW L , FLEMING KRISTEN N , CUI WENGE , OLSON RICHARD E
IPC分类号： A61P25/00 , A61K31/55 , C07D223/16
摘要： A compound of formulae I(A-E) having the following structure: R5* R 4 N, I(A-E) wherein: the carbon atom designated * is in the R or S configuration; X is phenyl, optionally substituted from 1 to 4 times with substituents as defined in R1 4 ; R' is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or gem-dimethyl; R3 is H, methyl, hydroxy, methoxy, fluoro, chloro, cyano, trifluoromethyl, or trifluoromethoxy; R4 is pyrimidinyl, optionally substituted from 1 to 4 times with substituents as defined below in R5 is H, fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, cyano, hydroxy or methoxy; R 6 is H, fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, cyano, hydroxy or methoxy; R7 is H, gem-dimethyl, or CI-C 4 alkyl, wherein each of the CI-C 4 alkyl is optionally substituted from 1 to 3 times with substituents as defined in R'5 ; R is H; R9 is H; R10 and R" are each independently selected from the group consisting of H, -C(O)R, CI-C 4 alkyl, C3 -C6 cycloalkyl, and C4-C7 cycloalkylalkyl, where each of CI-C 6 allyl, C3-C6 cycloalkyl, and C4 -C7 cycloalkylalkyl is optionally substituted from I to 3 times with substituents as defined below in R15; R' 0 and R" are each independently selected from the group consisting of phenyl, benzyl, and other 5- or 6-membered monocyclic heterocycles, where each of the phenyl, benzyl, and 5- or 6-membered monocyclic heterocycle is optionally substituted from 1 to 3 times with substituents as defined below in R14; R'0 and R" are taken together with the nitrogen to which they are attached to form a saturated or partially saturated monocyclic or fused bicyclic heterocycle selected from the group consisting of piperidine, pyrrolidine, morpholine, thiomorpholine, [1,2]oxazinane, isoxazolidine, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 3-oxomorpholino, 3-oxothiomorpholino, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-[1,2,4]triazolc[4,3-a]pyrazine, and other monocyclic or fused bicyclic heterocycles containing 1-4 heteroatoms selected from oxygen, nitrogen and sulfur, wherein the heterocycle is attached to the benzazepine core via the nitrogen atom, and is optionally substituted from I to 3 times with a substituent selected 12 independently at each occurrence thereof from the group consisting of halogen, cyano, -OR -NR 2 R1D, -S(O),R' 3 , -C(O)R 3, and Ci-C 4 alkyl, where each of CI-C 4 alkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; R' 0 and R1 are taken together with the nitrogen to which they are attached to form a heterocycle selected from the group consisting of piperazine, 2-oxopiperazinyl, 2-oxo-1,4 diazepanyl, 5-oxo-1,4-diazepanyl, 1,4-diazepane, and other heterocycles containing one additional nitrogen atom in the ring, where the heterocycle is optionally substituted on a ring carbon with from 1 to 3 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, cyano, -OR , -NR12 R 3 , -S(O),R' 3 , -C(O)R 3 , and CI-C 4 alkyl, or on the additional nitrogen atom from 1 to 3 times with a substituent selected independently at each occurrence thereof from the group consisting of S(O)nR'3 , C(O)R 3 , and CI-C 4 alkyl, wherein each of CI-C 4 alkyl is optionally substituted from I to 3 times with substituents as defined below in R15; R' 0 and R" are taken together with the nitrogen to which they are attached to form a heterocycle selected from the group consisting of piperazine, 2-oxopiperazinyl, 2-oxo-1,4 diazepanyl, 5-oxo-1,4-diazepanyl, 1,4-diazepane, and other heterocycles containing one additional nitrogen atom in the ring, where the heterocycle is optionally substituted on the additional nitrogen atom with a substituent selected independently at each occurrence thereof from the group consisting of phenyl, benzyl, and 5- or 6-membered aromatic heterocycles containing 1-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur, where each of the phenyl, benzyl, and 5- and 6-membered heterocycle is optionally substituted from 1 to 3 times with substituents as defined below in R' 4; R 2 is selected from the group consisting of H, CI-C 4 alkyl, C3-C6 cycloalkyl, C4 -C7 cycloalkylalkyl, and -C(O)R 1 3 , where each of CI-C 6 alkyl, C3 -C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from I to 3 times with substituents as defined below in R"; R 3 is CI-C 4 alkyl; R' 4 is independently selected at each occurrence from a substituent in the group consisting of halogen, -NO 2, -OR 2 , -NR"R", -NR C(O)2R 3, -NR'2 C(O)NR 2R , -S(O)n R 3, -CN, C(O)R 3 , CI-C 6 alkyl, C2-C6 alkenyl, C2 -C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl, wherein each of Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; and R 5 is independently selected at each occurrence from a substituent in the group consisting of CN, halogen, C(O)R 3 , CI-C 3 alkyl, -OR 2 , -NR' 0R", -S(O)nR13 , aryl, and heteroaryl, wherein each of the aryl or heteroaryl groups is optionally substituted from I to 4 times with substituents as defined above in R1 4; and n is 0, 1, or 2.

3. 发明专利

AU2006270071B2 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin 未知
公开(公告)号：AU2006270071B2
公开(公告)日：2012-02-02
申请号：AU2006270071
申请日：2006-07-17
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： MANNING DAVID D , NACRO KASSOUM , HU MIN , MOLINO BRUCE F , GUZZO PETER R , FLEMING KRISTEN N , ZHA CONGXIANG , ISHERWOOD MATTHEW L , OLSON RICHARD E , SAMBANDAM ARUNA , LIU SHUANG , CUI WENGE
IPC分类号： A61P25/00 , A61K31/55 , C07D223/16
摘要： The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II) where the carbon atom designated * is in the R or S configuration, and the substituents X and R-R are as defined herein.

4. 发明专利

AU2012202570B2 Aryl-and heteroaryl-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin 未知
公开(公告)号：AU2012202570B2
公开(公告)日：2014-01-16
申请号：AU2012202570
申请日：2012-05-02
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： MOLINO BRUCE F , LIU SHUANG , SAMBANDAM ARUNA , GUZZO PETER R , HU MIN , ZHA CONGXIANG , NACRO KASSOUM , MANNING DAVID D , ISHERWOOD MATTHEW L , FLEMING KRISTEN N , CUI WENGE , OLSON RICHARD E
IPC分类号： A61P25/00 , A61K31/55 , C07D223/16
摘要： A compound of formulae I(A-E) having the following structure: R5* R 4 N, I(A-E) wherein: the carbon atom designated * is in the R or S configuration; X is phenyl, optionally substituted from 1 to 4 times with substituents as defined in R1 4 ; R' is H, methyl, ethyl, or isopropyl; R2 is H, methyl, or gem-dimethyl; R3 is H, methyl, hydroxy, methoxy, fluoro, chloro, cyano, trifluoromethyl, or trifluoromethoxy; R4 is pyrimidinyl, optionally substituted from 1 to 4 times with substituents as defined below in R5 is H, fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, cyano, hydroxy or methoxy; R 6 is H, fluoro, chloro, methyl, trifluoromethyl, trifluoromethoxy, cyano, hydroxy or methoxy; R7 is H, gem-dimethyl, or CI-C 4 alkyl, wherein each of the CI-C 4 alkyl is optionally substituted from 1 to 3 times with substituents as defined in R'5 ; R is H; R9 is H; R10 and R" are each independently selected from the group consisting of H, -C(O)R, CI-C 4 alkyl, C3 -C6 cycloalkyl, and C4-C7 cycloalkylalkyl, where each of CI-C 6 allyl, C3-C6 cycloalkyl, and C4 -C7 cycloalkylalkyl is optionally substituted from I to 3 times with substituents as defined below in R15; R' 0 and R" are each independently selected from the group consisting of phenyl, benzyl, and other 5- or 6-membered monocyclic heterocycles, where each of the phenyl, benzyl, and 5- or 6-membered monocyclic heterocycle is optionally substituted from 1 to 3 times with substituents as defined below in R14; R'0 and R" are taken together with the nitrogen to which they are attached to form a saturated or partially saturated monocyclic or fused bicyclic heterocycle selected from the group consisting of piperidine, pyrrolidine, morpholine, thiomorpholine, [1,2]oxazinane, isoxazolidine, 2-oxopiperidinyl, 2-oxopyrrolidinyl, 3-oxomorpholino, 3-oxothiomorpholino, 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazine, 5,6,7,8-tetrahydro-[1,2,4]triazolc[4,3-a]pyrazine, and other monocyclic or fused bicyclic heterocycles containing 1-4 heteroatoms selected from oxygen, nitrogen and sulfur, wherein the heterocycle is attached to the benzazepine core via the nitrogen atom, and is optionally substituted from I to 3 times with a substituent selected 12 independently at each occurrence thereof from the group consisting of halogen, cyano, -OR -NR 2 R1D, -S(O),R' 3 , -C(O)R 3, and Ci-C 4 alkyl, where each of CI-C 4 alkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; R' 0 and R1 are taken together with the nitrogen to which they are attached to form a heterocycle selected from the group consisting of piperazine, 2-oxopiperazinyl, 2-oxo-1,4 diazepanyl, 5-oxo-1,4-diazepanyl, 1,4-diazepane, and other heterocycles containing one additional nitrogen atom in the ring, where the heterocycle is optionally substituted on a ring carbon with from 1 to 3 times with a substituent selected independently at each occurrence thereof from the group consisting of halogen, cyano, -OR , -NR12 R 3 , -S(O),R' 3 , -C(O)R 3 , and CI-C 4 alkyl, or on the additional nitrogen atom from 1 to 3 times with a substituent selected independently at each occurrence thereof from the group consisting of S(O)nR'3 , C(O)R 3 , and CI-C 4 alkyl, wherein each of CI-C 4 alkyl is optionally substituted from I to 3 times with substituents as defined below in R15; R'0 and R" are taken together with the nitrogen to which they are attached to form a heterocycle selected from the group consisting of piperazine, 2-oxopiperazinyl, 2-oxo-1,4 diazepanyl, 5-oxo-1,4-diazepanyl, 1,4-diazepane, and other heterocycles containing one additional nitrogen atom in the ring, where the heterocycle is optionally substituted on the additional nitrogen atom with a substituent selected independently at each occurrence thereof from the group consisting of phenyl, benzyl, and 5- or 6-membered aromatic heterocycles containing 1-3 heteroatoms selected from the group consisting of oxygen, nitrogen, and sulfur, where each of the phenyl, benzyl, and 5- and 6-membered heterocycle is optionally substituted from 1 to 3 times with substituents as defined below in R' 4; R 2 is selected from the group consisting of H, CI-C 4 alkyl, C3-C6 cycloalkyl, C4 -C7 cycloalkylalkyl, and -C(O)R 1 3 , where each of CI-C 6 alkyl, C3 -C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from I to 3 times with substituents as defined below in R"; R 3 is CI-C 4 alkyl; R' 4 is independently selected at each occurrence from a substituent in the group consisting of halogen, -NO 2, -OR 2 , -NR"R", -NR C(O)2R 3, -NR'2 C(O)NR 2R , -S(O)n R 3, -CN, C(O)R 3 , CI-C 6 alkyl, C2-C6 alkenyl, C2 -C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl, wherein each of Ci-C 6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, C3-C6 cycloalkyl, and C4-C7 cycloalkylalkyl is optionally substituted from 1 to 3 times with substituents as defined below in R15; and R 5 is independently selected at each occurrence from a substituent in the group consisting of CN, halogen, C(O)R 3 , CI-C 3 alkyl, -OR 2 , -NR' 0R", -S(O)nR13 , aryl, and heteroaryl, wherein each of the aryl or heteroaryl groups is optionally substituted from I to 4 times with substituents as defined above in R1 4; and n is 0, 1, or 2.

5. 发明专利

EA017308B1 АРИЛОКСИ- И ГЕТЕРОАРИЛОКСИЗАМЕЩЕННЫЕ ТЕТРАГИДРОБЕНЗАЗЕПИНЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ БЛОКИРОВКИ ОБРАТНОГО ЗАХВАТА НОРЭПИНЕФРИНА, ДОПАМИНА И СЕРОТОНИНА 未知
公开(公告)号：EA017308B1
公开(公告)日：2012-11-30
申请号：EA200971045
申请日：2008-05-08
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： LIU SHUANG , YANG YUH-LIN ALLEN , SAMBANDAM ARUNA , MOLINO BRUCE F , OLSON RICHARD E
IPC分类号： A61K31/55 , C07D223/16
摘要： Соединения, являющиесяарилокси- игетероарилоксизамещеннымитетрагидробензазепиновымипроизводными, понастоящемуизобретениюпредставленыформулами (I)(A-E), имеющимиследующуюструктуру, гдеатомуглерода, обозначенный *, имеет R- или S-конфигурацию, изаместители X и R-Rпредставлены, какопределенов настоящемизобретении. Фармацевтическиекомпозиции, содержащиетерапевтическиэффективныеколичествазаявленныхсоединений, испособлечениярасстройства, котороевызваноилизависитотсниженнойдоступностинорэпинефрина, допаминаилисеротонина, сиспользованиемзаявленныхсоединений.

6. 发明专利

PH12014501033A1 ARYL-AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN 未知
公开(公告)号：PH12014501033A1
公开(公告)日：2014-09-22
申请号：PH12014501033
申请日：2014-01-27
申请人： ALBANY MOLECULAR RES INC
发明人： MOLINO BRUCE F , SHUANG LIU , ARUNA SAMBANDAM , GUZZO PETER R , MIN HU , CONGXIANG ZHA , KASSOUM NACRO , MANNING DAVID D , ISHERWOOD MATTHEW L , FLEMING KRISTEN N , WENGE CUI , OLSON RICHARD E
IPC分类号： A61K31/55 , A61K45/00 , A61P11/00 , A61P25/00 , C07D223/16 , C07D401/04
摘要： The compounds of the present invention are represented by the following aryl- and heteroaryl-substituted tetrahydrobenzazepine and dihydrobenzazapine derivatives having formulae I(A-E) and formula (II) where the carbon atom designated * is in the R or S configuration, and the substituents X and R1-R9 are as defined herein.

7. 发明专利

EA017249B8 АРИЛ- И ГЕТЕРОАРИЛЗАМЕЩЕННЫЕ ТЕТРАГИДРОБЕНЗО-1,4-ДИАЗЕПИНЫ И ИХ ПРИМЕНЕНИЕ ДЛЯ БЛОКИРОВАНИЯ ОБРАТНОГО ЗАХВАТА НОРЭПИНЕФРИНА, ДОПАМИНА И СЕРОТОНИНА 未知
公开(公告)号：EA017249B8
公开(公告)日：2013-01-30
申请号：EA200971044
申请日：2008-05-08
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： GUZZO PETER R , MOLINO BRUCE F , CUI WENGE , LIU SHUANG , OLSON RICHARD E , YET LARRY
IPC分类号： A61K31/55 , C07D223/16
摘要： Арил- игетероарилзамещенныепроизводныететрагидробензо-1,4-диазепиновыесоединениянастоящегоизобретенияпредставленыформулой I(A-D), имеющейследующуюструктуру:гдезаместители X и R-Rимеютуказанныев описаниизначения.

8. 发明专利

AU2008251558B2 Aryloxy-and heteroaryloxy-substituted tetrahydrobenzazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin 未知
公开(公告)号：AU2008251558B2
公开(公告)日：2012-12-20
申请号：AU2008251558
申请日：2008-05-08
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： YANG YUH-LIN ALLEN , SAMBANDAM ARUNA , OLSON RICHARD E , LIU SHUANG , MOLINO BRUCE F
IPC分类号： C07D223/16 , A61K31/55
摘要： The aryloxy- and heteroaryloxy-substituted tetrahydrobenzazepine derivative compounds of the present invention are represented by formulae (I) (A-E) having the following structure where the carbon atom designated * is in the R or S configuration and the substituents X and R

9. 发明专利

NZ580801A ARYL- AND HETEROARYL-SUBSTITUTED TETRAHYDROBENZO-1,4-DIAZEPINES AND USE THEREOF TO BLOCK REUPTAKE OF NOREPINEPHRINE, DOPAMINE, AND SEROTONIN 未知
公开(公告)号：NZ580801A
公开(公告)日：2012-09-28
申请号：NZ58080108
申请日：2008-05-08
申请人： SQUIBB BRISTOL MYERS CO , ALBANY MOLECULAR RES INC , LARRY YET
发明人： YET LARRY , GUZZO PETER R , MOLINO BRUCE F , CUI WENGE , LIU SHUANG , OLSON RICHARD E
IPC分类号： C07D243/14 , A61K31/5513
摘要： Disclosed are 1-aryl-4-alkyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepines as represented by the general formula I(A-D), wherein: X represents a phenyl, benzo[1,3]dioxolyl, or naphthyl each optionally substituted from 1 to 3 times with halogen, -S(O)2R14, CN, or alkyl which may be optionally substituted with R10; R1 is alkyl; R2, R3, R5, R6, R7 and R8 are each hydrogen; R4 is halogen, NR12R13 or else R4 is piperazinyl, phenyl, pyridyl, 2-oxo-pyridin-1-yl, pyrimidinyl, pyridazinyl, pyrazinyl, triazinyl, pyrazolyl, [1,2,4]triazolo[4,3-a]pyridinyl or [1,2,4]triazolo[1,5-a]pyridinyl, optionally substituted from 1 to 4 times R9; R9 is independently selected at each occurrence from NR12R13, S(O)2R14, C(O)R15 or alkyl which may be optionally substituted with R10; R10 is halogen; R12 and R13 are each independently H or a 5 or 6-membered monocyclic heterocycle; R14 is alkyl; R15is NR12R13; or a pharmaceutically acceptable salt thereof. Representative compounds include 7 -fluoro-4-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[e ][1,4]diazepine, 7-fluoro-1-(3-fluorophenyl)-4-methyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine, 1-(benzo[d][1,3]dioxol-5-yl)-4-methyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine and 7-(4-(ethylsulfonyl)piperazin-1-yl)-4-methyl-1-phenyl-2,3,4,5-tetrahydro-1H-benzo[e][1,4]diazepine. Further disclosed is a pharmaceutical composition which comprises a pharmaceutically acceptable carrier and a therapeutically effective amount of the compound as defined above, for treating a disorder selected from pain, attention deficit hyperactivity disorder (ADHD), cognition impairment, anxiety disorders, panic disorder, bipolar disorder, manic depression, obsessive compulsive disorder (OCD), posttraumatic stress disorder (PTSD), acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder (PMDD), social anxiety disorder (SAD), major depressive disorder (MDD), postnatal depression, dysthymia, depression associated with Alzheimer's disease, Parkinson's disease, obesity, anorexia nervosa, bulimia nervosa, binge eating disorder, analgesia, substance abuse disorders, chemical dependencies, drug addiction, neurodegenerative diseases, Parkinson's disease, sleep related eating disorder, stress urinary incontinence (SUI), migraine, diabetic neuropathy, fibromyalgia syndrome (FS), chronic fatigue syndrome (CFS), sexual dysfunction, premature ejaculation, male impotence, and thermoregulatory disorders.

10. 发明专利

AU2008251557B2 Aryl- and heteroaryl-substituted tetrahydrobenzo-1,4-diazepines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin 未知
公开(公告)号：AU2008251557B2
公开(公告)日：2012-12-06
申请号：AU2008251557
申请日：2008-05-08
申请人： ALBANY MOLECULAR RES INC , SQUIBB BRISTOL MYERS CO
发明人： MOLINO BRUCE F , LIU SHUANG , CUI WENGE , GUZZO PETER R , OLSON RICHARD E , YET LARRY
IPC分类号： C07D223/16 , A61K31/55
摘要： The aryl- and heteroaryl-substituted tetrahydrobenzo-l,4-diazepine derivative compounds of the present invention are represented by formulae 1(A-D) having the following structure: where the substituents X and R -R are as defined herein.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式